Dipeptidyl Peptidase-4 Inhibitors and Alpha-cell Recovery
Summary
Hypoglycaemia is a well-known complication of insulin treated diabetes. The counterregulatory response to hypoglycaemia, with glucagon as the most important mediator, is initially diminished within a few years of onset of Type 1 diabetes and subsequently lost and thus increasing the risk of hypoglycaemia. Dipeptidyl Peptidase (DPP)-4 inhibitors augment the glucagon response to insulin-induced hypoglycaemia in type 2 diabetes. The investigators hypothesize that treatment with a DPP-4 inhibitor in patients with type 1 diabetes will recover the alpha cell response to hypoglycaemia.
Timeline
- Start
- 2011-03
- Primary completion
- 2012-06
- Completion
- 2012-10
Outcome
Missed primary endpoint
registry analysis (superiority or other test); Baseline vs Sitagliptin Treatment vs Placebo; p = 1.0; ANOVA NCT01272583 ↗
registry analysis (superiority or other test); Baseline vs Sitagliptin Treatment vs Placebo; p = 0.98; ANOVA NCT01272583 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sitagliptin | Small molecule | 100 mg | — |